Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

23

Revenue 2017

Copaxone

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Copaxone was produced by Teva and Sanofi.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure

of a weak market for its generic drugs and declining sales of former cash cow Copaxone (glatiramer acetate) for multiple sclerosis.

Teva names new CFO and bulks up its opioid liability fund

Teva names new CFO and bulks up its opioid liability fund Teva’s third-quarter results were hit once again by weak generic sales and the continuing erosion of multiple sclerosis therapy Copaxone (glatiramer acetate) which has lost patent protection and is

Sandoz finally wins FDA approval for Neulasta biosimilar

Sandoz finally wins FDA approval for Neulasta biosimilar This includes all biosimilars, biopharmaceutical contract manufacturing and Glatopa sales – Sandoz’ generic of Teva’s multiple sclerosis drug Copaxone.

Biogen trumpets safety data for Tecfidera follow-up

Biogen trumpets safety data for Tecfidera follow-up The patients – who were either newly-diagnosed cases or had previously been switched from injectable beta interferon drugs or Teva’s Copaxone (glatiramer acetate) – also saw the mean number of

Teva’s migraine injection approved in Europe

Teva’s migraine injection approved in Europe Its income is expected to slip 8% to 10% in 2019, thanks to the decline of its biggest seller, MS drug Copaxone. To reverse the trend, Teva needs Ajovy (fremanezumab) and

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics